RxDoctor Payments Data

Daniel Zalkind, MD

Cardiovascular Disease · Covington, KYNPI 1538315700

Payments from drug & device makers

$1,650in general payments, 2019–2025

Across 108 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$269
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$200
  • Pfizer$186
  • Amgen$185
  • Johnson & Johnson$169
  • Sanofi-aventis U.S. LLC$125
  • plus $517 from 14 others

What the payments were for

  • Food & beverage$1,61898%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,650 in reported general payments places this provider in the 35th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$128,402
Medicare patients
1,454
Services billed
2,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban336$338,001
EntrestoSacubitril/Valsartan69$114,885
XareltoRivaroxaban51$70,107
Repatha SureclickEvolocumab34$39,044
MounjaroTirzepatide24$33,376
FarxigaDapagliflozin Propanediol24$22,273
JardianceEmpagliflozin12$21,388
WegovySemaglutide14$18,489
VascepaIcosapent Ethyl18$9,641
Metoprolol Succinate388$4,737
Atorvastatin Calcium512$4,182
Ranolazine ErRanolazine15$2,384
Furosemide376$1,941
Carvedilol342$1,904
Diltiazem 24hr Er (Cd)Diltiazem Hcl88$1,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$186$338,001336 claims
NovartisEntresto$269$114,88569 claims
Johnson & JohnsonXarelto$169$70,10751 claims
AstraZenecaFarxiga$119$22,27324 claims
Boehringer IngelheimJardiance$39$21,38812 claims
Novo NordiskWegovy$17$18,48914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Covington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →